A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT03784677. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Study identification
- NCT ID
- NCT03784677
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Enrollment
- 11 participants
Conditions and interventions
Conditions
- Advanced Malignant Solid Neoplasm
- Refractory Malignant Solid Neoplasm
- Refractory Ovarian Carcinoma
- Refractory Pancreatic Carcinoma
- Stage II Pancreatic Cancer AJCC v8
- Stage IIA Pancreatic Cancer AJCC v8
- Stage IIB Pancreatic Cancer AJCC v8
- Stage III Ovarian Cancer AJCC v8
- Stage III Pancreatic Cancer AJCC v8
- Stage III Prostate Cancer AJCC v8
- Stage IIIA Ovarian Cancer AJCC v8
- Stage IIIA Prostate Cancer AJCC v8
- Stage IIIB Ovarian Cancer AJCC v8
- Stage IIIB Prostate Cancer AJCC v8
- Stage IIIC Ovarian Cancer AJCC v8
- Stage IIIC Prostate Cancer AJCC v8
- Stage IV Ovarian Cancer AJCC v8
- Stage IV Pancreatic Cancer AJCC v8
- Stage IV Prostate Cancer AJCC v8
- Stage IVA Ovarian Cancer AJCC v8
- Stage IVA Prostate Cancer AJCC v8
- Stage IVB Ovarian Cancer AJCC v8
- Stage IVB Prostate Cancer AJCC v8
Interventions
- TRPV6 Calcium Channel Inhibitor SOR-C13 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 28, 2019
- Primary completion
- Jun 19, 2023
- Completion
- Jun 19, 2023
- Last update posted
- Nov 17, 2023
2019 – 2023
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| M D Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03784677, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 17, 2023 · Synced May 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03784677 live on ClinicalTrials.gov.